Genetic association and interaction analysis of USF1 and APOA5 on lipid levels and atherosclerosis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 30, Issue 2, 2010, Pages 346-352

  Laurila, Pirkka Pekka ^a   Naukkarinen, Jussi ^a   Kristiansson, Kati ^a,b   Ripatti, Samuli ^a   Kauttu, Tuuli ^a   Silander, Kaisa ^a   Salomaa, Veikko ^c   Perola, Markus ^a   Karhunen, Pekka J ^d   Barter, Philip J ^e   Ehnholm, Christian ^a   Peltonen, Leena ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^e HEART RESEARCH INSTITUTE   (Australia)

Author keywords

APOA5; Atherosclerosis; Epistasis; Genes; Lipids; USF1

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TRIACYLGLYCEROL;

ABDOMINAL AORTA; ADULT; AGED; ALLELE; AORTA ATHEROSCLEROSIS; APOA5 GENE; ARTICLE; ATHEROGENESIS; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EPISTASIS; FEMALE; FIBROSIS; GENE; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLUCOSE METABOLISM; HUMAN; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; USF1 GENE;

ADULT; AORTA, ABDOMINAL; AORTIC DISEASES; APOLIPOPROTEINS A; ATHEROSCLEROSIS; AUSTRALIA; AUTOPSY; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DYSLIPIDEMIAS; EPISTASIS, GENETIC; FEMALE; FIBROSIS; FINLAND; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIPIDS; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; TRIGLYCERIDES; UPSTREAM STIMULATORY FACTORS;

EID: 75149172789     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.109.188912     Document Type: Article

References (34)

1. Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases. Hum Hered. 2003;56:73-82.
2. Naukkarinen J, Gentile M, Soro-Paavonen A, Saarela J, Koistinen HA, Pajukanta P, Taskinen MR, Peltonen L. USF1 and dyslipidemias: converging evidence for a functional intronic variant. Hum Mol Genet. 2005;14:2595-2605.
3. Putt W, Palmen J, Nicaud V, Tregouet DA, Tahri-Daizadeh N, Flavell DM, Humphries SE, Talmud PJ. Variation in USF1 shows haplotype effects, gene:gene and gene:environment associations with glucose and lipid parameters in the European Atherosclerosis Research Study II. Hum Mol Genet. 2004;13:1587-1597.
4. Pajukanta P, Lilja HE, Sinsheimer JS, Cantor RM, Lusis AJ, Gentile M, Duan XJ, Soro-Paavonen A, Naukkarinen J, Saarela J, Laakso M, Ehnholm C, Taskinen MR, Peltonen L. Familial combined hyperlipid-emia is associated with upstream transcription factor 1 (USF1). Nat Genet. 2004;36:371-376.
5. Ng MC, Miyake K, So WY, Poon EW, Lam VK, Li JK, Cox NJ, Bell GI, Chan JC. The linkage and association of the gene encoding upstream stimulatory factor 1 with type 2 diabetes and metabolic syndrome in the Chinese population. Diabetologia. 2005;48:2018-2024.
6. Auro K, Kristiansson K, Zethelius B, Berne C, Lannfelt L, Taskinen MR, Jauhiainen M, Perola M, Peltonen L, Syvanen AC. USF1 gene variants contribute to metabolic traits in men in a longitudinal 32-year follow-up study. Diabetologia. 2008;51:464-472.
7. Komulainen K, Alanne M, Auro K, Kilpikari R, Pajukanta P, Saarela J, Ellonen P, Salminen K, Kulathinal S, Kuulasmaa K, Silander K, Salomaa V, Perola M, Peltonen L. Risk alleles of USF1 gene predict cardiovascular disease of women in two prospective studies. PLoS Genet. 2006; 2:e69.
8. Kristiansson K, Ilveskoski E, Lehtimaki T, Peltonen L, Perola M, Karhunen PJ. Association analysis of allelic variants of USF1 in coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2008;28:983-989.
9. Reiner AP, Carlson CS, Jenny NS, Durda JP, Siscovick DS, Nickerson DA, Tracy RP. USF1 gene variants, cardiovascular risk, and mortality in European Americans: analysis of two US cohort studies. Arterioscler Thromb Vasc Biol. 2007;27:2736-2742.
10. Pennacchio LA, Olivier M, Hubacek JA, Cohen JC, Cox DR, Fruchart JC, Krauss RM, Rubin EM. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 2001; 294:169-173.
11. Silander K, Alanne M, Kristiansson K, Saarela O, Ripatti S, Auro K, Karvanen J, Kulathinal S, Niemela M, Ellonen P, Vartiainen E, Jousilahti P, Saarela J, Kuulasmaa K, Evans A, Perola M, Salomaa V, Peltonen L. Gender differences in genetic risk profiles for cardiovascular disease. PLoS ONE. 2008;3:e3615.
12. Nabika T, Nasreen S, Kobayashi S, Masuda J. The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis. 2002;165:201-204.
13. Aouizerat BE, Kulkarni M, Heilbron D, Drown D, Raskin S, Pullinger CR, Malloy MJ, Kane JP. Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res. 2003;44:1167-1173.
14. Hodoglugil U, Tanyolac S, Williamson DW, Huang Y, Mahley RW. Apolipoprotein A-V: a potential modulator of plasma triglyceride levels in Turks. J Lipid Res. 2006;47:144-153.
15. Yamada Y, Kato K, Hibino T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Ichihara S, Yoshida H, Satoh K, Nozawa Y. Prediction of genetic risk for metabolic syndrome. Atherosclerosis. 2007;191:298-304. (Pubitemid 46400713)
16. Nowak M, Helleboid-Chapman A, Jakel H, Martin G, Duran-Sandoval D, Staels B, Rubin EM, Pennacchio LA, Taskinen MR, Fruchart-Najib J, Fruchart JC. Insulin-mediated down-regulation of apolipoprotein A5 gene expression through the phosphatidylinositol 3-kinase pathway: role of upstream stimulatory factor. Mol Cell Biol. 2005;25:1537-1548.
17. Wyszynski DF, Waterworth DM, Barter PJ, Cohen J, Kesaniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Sharma SS, Nolan V, Middleton LT, Sundseth SS, Farrer LA, Mooser V, Grundy SM. Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). Am J Cardiol. 2005;95:194-198.
18. Ilveskoski E, Perola M, Lehtimaki T, Laippala P, Savolainen V, Pajarinen J, Penttila A, Lalu KH, Mannikko A, Liesto KK, Koivula T, Karhunen PJ. Age-dependent association of apolipoprotein E genotype with coronary and aortic atherosclerosis in middle-aged men: an autopsy study. Circulation. 1999;100:608-613.
19. Mikkelsson J, Perola M, Wartiovaara U, Peltonen L, Palotie A, Penttila A, Karhunen PJ. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism, coronary thrombosis, and myocardial infarction in middle-aged Finnish men who died suddenly. Thromb Haemost. 2000; 84:78-82.
20. Vartiainen E, Jousilahti P, Alfthan G, Sundvall J, Pietinen P, Puska P. Cardiovascular risk factor changes in Finland, 1972-1997. Int J Epidemiol. 2000;29:49-56.
21. Pastinen T, Raitio M, Lindroos K, Tainola P, Peltonen L, Syvanen AC. A system for specific, high-throughput genotyping by allele-specific primer extension on microarrays. Genome Res. 2000;10:1031-1042.
22. O'Connell JR, Weeks DE. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am J Hum Genet. 1998; 63:259-266.
23. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265.
24. Talmud PJ, Palmen J, Putt W, Lins L, Humphries SE. Determination of the functionality of common APOA5 polymorphisms. J Biol Chem. 2005;280:28215-28220.
25. Horinek A, Vrablik M, Ceska R, Adamkova V, Poledne R, Hubacek JA. T-1131-> C polymorphism within the apolipoprotein AV gene in hyper-triglyceridemic individuals. Atherosclerosis. 2003;167:369-370.
26. Lee JC, Weissglas-Volkov D, Kyttala M, Sinsheimer JS, Jokiaho A, de Bruin TW, Lusis AJ, Brennan ML, van Greevenbroek MM, van der Kallen CJ, Hazen SL, Pajukanta P. USF1 contributes to high serum lipid levels in Dutch FCHL families and U.S. whites with coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2222-2227.
27. Zeggini E, Damcott CM, Hanson RL, Karim MA, Rayner NW, Groves CJ, Baier LJ, Hale TC, Hattersley AT, Hitman GA, Hunt SE, Knowler WC, Mitchell BD, Ng MC, O'Connell JR, Pollin TI, Vaxillaire M, Walker M, Wang X, Whittaker P, Xiang K, Jia W, Chan JC, Froguel P, Deloukas P, Shuldiner AR, Elbein SC, McCarthy MI. Variation within the gene encoding the upstream stimulatory factor 1 does not influence susceptibility to type 2 diabetes in samples from populations with replicated evidence of linkage to chromosome 1q. Diabetes. 2006;55: 2541-2548.
28. Huertas-Vazquez A, Aguilar-Salinas C, Lusis AJ, Cantor RM, Canizales-Quinteros S, Lee JC, Mariana-Nunez L, Riba-Ramirez RM, Jokiaho A, Tusie-Luna T, Pajukanta P. Familial combined hyperlipidemia in Mexicans: association with upstream transcription factor 1 and linkage on chromosome 16q24.1. Arterioscler Thromb Vasc Biol. 2005;25: 1985-1991.
29. Elosua R, Ordovas JM, Cupples LA, Lai CQ, Demissie S, Fox CS, Polak JF, Wolf PA, D'Agostino RB Sr, O'Donnell CJ. Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res. 2006;47:990-996.
30. Maasz A, Kisfali P, Szolnoki Z, Hadarits F, Melegh B. Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke. J Neurol. 2008;255:649-654.
31. Li J, Xu HW, Zhu XY. Association of APOA5 gene polymorphism with levels of lipids and atherosclerotic cerebral infarction [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2007;24:576-578.
32. Haim M, Benderly M, Brunner D, Behar S, Graff E, Reicher-Reiss H, Goldbourt U. Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. Circulation. 1999;100:475-482.
33. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 2000;86:943-949.
34. Talmud PJ, Martin S, Taskinen MR, Frick MH, Nieminen MS, Kesaniemi YA, Pasternack A, Humphries SE, Syvanne M. APOA5 gene variants, lipoprotein particle distribution, and progression of coronary heart disease: results from the LOCAT study. J Lipid Res. 2004;45: 750-756.